ClinicalTrials.gg

TargetBeta

KDR

kinase insert domain receptor · also FLK1, VEGFR, VEGFR2, CD309 · CD molecules

15 programs in company-led studies act on KDR, from 14 companies: 9 in phase 3, 4 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (15 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
cabozantinibruleExelixisphase 43610 runningMETChEMBL
lenvatinibruleEisaiphase 4815 runningFLT1, FLT4NCIt
regorafenibruleBayerphase 4404 runningABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEKChEMBL
nintedanibruleBoehringer Ingelheimphase 4761 runningFGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, PDGFRA, PDGFRBChEMBL
zanzalintinibruleExelixisphase 31715 runningAXL, METNCIt
apatinibruleJiangsu HengRui Medicinephase 3478 running–ChEMBL
anlotinibruleSino Biopharmaceuticalphase 3407 runningFLT4, KIT, PDGFRBChEMBL
AXL/FLT3/VEGFR2 Inhibitor KC1036ruleBeijing Konruns Pharmaceuticalphase 376 runningAXL, FLT3NCIt
RamucirumabruleEli Lillyphase 3585 running–NCIt
vorolanibruleBetta Pharmaceuticalsphase 3245 running–the studies' text
AxitinibrulePfizerphase 3454 runningFLT1, FLT4ChEMBL
chiauranibruleChipscreen Biosciencesphase 3154 runningAURKB, FLT1, FLT4ChEMBL
Aurora B/VEGFR/FGFR Inhibitor AL8326ruleAdvenchen Laboratories Nanjingphase 384 running–NCIt
cp-547632rulePanOpticaphase 261 running–ChEMBL
Anti-PD-1/Anti-VEGFR2 Bispecific Antibody OTP-01ruleOttimo Pharmaphase 211 runningPDCD1NCIt

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.